- Home
- VRNA vs AMG Comparison
VRNA vs AMG Comparison
Compare VRNA & AMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- AMG
- Stock Information
- Founded
- VRNA 2005
- AMG 1993
- Country
- VRNA United Kingdom
- AMG United States
- Employees
- VRNA N/A
- AMG N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- AMG Investment Managers
- Sector
- VRNA Health Care
- AMG Finance
- Exchange
- VRNA Nasdaq
- AMG Nasdaq
- Market Cap
- VRNA 8.3B
- AMG 6.7B
- IPO Year
- VRNA 2017
- AMG 1997
- Fundamental
- Price
- VRNA $106.27
- AMG $234.54
- Analyst Decision
- VRNA Buy
- AMG Strong Buy
- Analyst Count
- VRNA 11
- AMG 5
- Target Price
- VRNA $114.10
- AMG $250.80
- AVG Volume (30 Days)
- VRNA 1.3M
- AMG 175.2K
- Earning Date
- VRNA 11-03-2025
- AMG 11-03-2025
- Dividend Yield
- VRNA N/A
- AMG 0.02%
- EPS Growth
- VRNA N/A
- AMG N/A
- EPS
- VRNA N/A
- AMG 13.84
- Revenue
- VRNA $221,673,000.00
- AMG $2,030,400,000.00
- Revenue This Year
- VRNA $896.59
- AMG $3.04
- Revenue Next Year
- VRNA $77.56
- AMG $9.32
- P/E Ratio
- VRNA N/A
- AMG $16.97
- Revenue Growth
- VRNA N/A
- AMG 0.11
- 52 Week Low
- VRNA $27.54
- AMG $139.22
- 52 Week High
- VRNA $106.45
- AMG $238.29
- Technical
- Relative Strength Index (RSI)
- VRNA 68.40
- AMG 67.45
- Support Level
- VRNA $106.15
- AMG $228.53
- Resistance Level
- VRNA $106.42
- AMG $238.29
- Average True Range (ATR)
- VRNA 0.19
- AMG 4.36
- MACD
- VRNA -0.17
- AMG -0.06
- Stochastic Oscillator
- VRNA 76.32
- AMG 74.71
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About AMG Affiliated Managers Group Inc.
Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of June 2025, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 19% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (24%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (57%)—had $771 billion in managed assets.